U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07377253) titled 'First-in-Human Study Testing a New Antibody Treatment for Tick-Borne Encephalitis in Healthy Volunteers.' on Nov. 18, 2025.
Brief Summary: The goal of this clinical trial is to evaluate the safety, tolerability, and pharmacokinetics of the investigational monoclonal antibody TBE025 when given intravenously to healthy adult volunteers aged 18 to 55.
The study aims to determine the recommended Phase II dose of TBE025 and to assess the incidence and severity of adverse events related to its administration.
There is no comparison group, as this is a single-arm, open-label study. Participants will receive a single intravenous infusion ...